Abbonarsi

Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia - 26/11/21

Doi : 10.1016/j.ahj.2021.09.008 
Kevin R. Bainey, MD, MSc a, , Jerome L. Fleg, MD b, Judith S. Hochman, MD c, Dennis F. Kunichoff, MPH c, Rebecca Anthopolos, DrPH c, Alexander M. Chernyavskiy, MD, PhD d, Marcin Demkow, MD e, Juan-Manuel Lopez-Quijano, MD, MsC f, Jorge Escobedo, MD g, Kian Keong Poh, MD h, Ruben B. Ramos, MD i, Eduardo G. Lima, MD, PhD j, Herwig Schuchlenz, MD k, Ziad A. Ali, MD, DPhil l, m, n, Gregg W. Stone, MD o, David J. Maron, MD p, Sean M. O'Brien, PhD q, John A. Spertus, MD, MPH r, Sripal Bangalore, MD, MHA c
a Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada 
b National Heart Lung and Blood Institute, Bethesda, MD 
c NYU Grossman School of Medicine, New York, NY 
d E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation (E.Meshalkin NMRC), Novosibirsk, Russia 
e Department of Coronary and Structural Heart Diseases, National Institute of Cardiology, Warsaw, Poland 
f Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico 
g Instituto Mexicano del Seguro Social, Mexico City, Mexico 
h National University Heart Center Singapore and Yong Loo Lin School of Medicine, National University of Singapore, Singapore 
i Hospital de Santa Marta, Lisboa, Portugal 
j Heart Institute, InCor-HCFMUSP, Sao Paulo, Brazil 
k oLKH Graz II, Department fuer Kardiologie und Intensivmedizin, Graz, Austria 
l Cardiovascular Research Foundation, New York, NY 
m Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY 
n St Francis Hospital, Roslyn, NY 
o Icahn School of Medicine at Mount Sinai, New York, NY 
p Stanford University School of Medicine, Stanford, CA 
q Duke Clinical Research Institute and Duke University, Durham, NC 
r Saint Luke's Mid America Heart Institute/University of Missouri - Kansas City (UMKC), Kansas City, MO 

Reprint requests: Kevin R. Bainey, MD, MSc, University of Alberta Hospital, 2C2 Walter Mackenzie, Edmonton, Alberta, Canada.University of Alberta Hospital2C2 Walter MackenzieEdmontonAlbertaCanada

Riassunto

Background

The ISCHEMIA-CKD (International Study of Comparative Health Effectiveness with Medical and Invasive Approaches–Chronic Kidney Disease) trial found no advantage to an invasive strategy compared to conservative management in reducing all-cause death or myocardial infarction (D/MI). However, the prognostic influence of angiographic coronary artery disease (CAD) burden and ischemia severity remains unknown in this population. We compared the relative impact of CAD extent and severity of myocardial ischemia on D/MI in patients with advanced chronic kidney disease (CKD).

Methods

Participants randomized to invasive management with available data on coronary angiography and stress testing were included. Extent of CAD was defined by the number of major epicardial vessels with ≥50% diameter stenosis by quantitative coronary angiography. Ischemia severity was assessed by site investigators as moderate or severe using trial definitions. The primary endpoint was D/MI.

Results

Of the 388 participants, 307 (79.1%) had complete coronary angiography and stress testing data. D/MI occurred in 104/307 participants (33.9%). Extent of CAD was associated with an increased risk of D/MI (P < .001), while ischemia severity was not (P = .249). These relationships persisted following multivariable adjustment. Using 0-vessel disease (VD) as reference, the adjusted hazard ratio (HR) for 1VD was 1.86, 95% confidence interval (CI) 0.94 to 3.68, P = .073; 2VD: HR 2.13, 95% CI 1.10 to 4.12, P = .025; 3VD: HR 4.00, 95% CI 2.06 to 7.76, P < .001. Using moderate ischemia as the reference, the HR for severe ischemia was 0.84, 95% CI 0.54 to 1.30, P = .427.

Conclusion

Among ISCHEMIA-CKD participants randomized to the invasive strategy, extent of CAD predicted D/MI whereas severity of ischemia did not.

Il testo completo di questo articolo è disponibile in PDF.

ABBREVIATIONS & ACRONYMS : CCTA, CCD, CKD, D/MI, eGFR, ETT, GDMT, ISCHEMIA-CKD, QCA, VD


Mappa


 This paper was handled by Guest Editor (Dhaval Kolte, MD, PhD. Clin. Inv.)


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 243

P. 187-200 - Gennaio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes
  • Yang Xu, Edouard L. Fu, Marco Trevisan, Tomas Jernberg, Arvid Sjölander, Catherine M Clase, Juan-Jesus Carrero
| Articolo seguente Articolo seguente
  • Associations between neighborhood socioeconomic cluster and hypertension, diabetes, myocardial infarction, and coronary artery disease within a cohort of cardiac catheterization patients
  • Anne M. Weaver, Laura A. McGuinn, Lucas Neas, Robert B. Devlin, Radhika Dhingra, Cavin K. Ward-Caviness, Wayne E. Cascio, William E. Kraus, Elizabeth R. Hauser, David Diaz-Sanchez

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.